Passage Bio, Inc. Form 8-K Summary
Reporting date: October 10, 2022. The filing reports a management change under Item 5.02; it does not provide quarterly or annual financial results.
Business Context and Reporting Period
Passage Bio is a clinical-stage gene therapy company. Effective October 10, 2022, the board appointed William Chou, M.D. as Chief Executive Officer and a Class II director, with an initial term expiring at the 2025 Annual Meeting of Stockholders. Interim CEO Edgar B. “Chip” Cale resigned from that role and will remain General Counsel and Corporate Secretary.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, operating margins, debt, cash balances, liquidity measures, or other financial statement metrics.
Material Changes and Compensation Arrangements
- Dr. Chou will receive an annual base salary of $580,000 and will be eligible for an annual cash bonus of up to 55% of base salary, subject to performance criteria.
- He will receive a $200,000 sign-on bonus, subject to full or partial repayment under specified resignation or termination circumstances during the first 18 months.
- The company will reimburse commuting and housing expenses, with housing reimbursement capped at $7,500 per month.
- Dr. Chou will receive an option to purchase 885,000 common shares at an exercise price equal to the stock’s closing price on the grant date. The option vests 25% after one year and monthly thereafter over the remaining vesting period, subject to continued service.
- Upon termination without Cause or resignation for Good Reason, subject to a release, he may receive 12 months of base salary, his target bonus, and 12 months of COBRA premiums. Certain change-in-control circumstances increase severance to 18 months of base salary and COBRA premiums, 150% of target bonus, and accelerated vesting of outstanding equity awards.
Outlook, Risks and Unusual Items
The filing provides no operating guidance or business outlook. The principal disclosed items are the new CEO’s compensation, severance protections, potential change-in-control benefits, and equity award, which may affect future compensation expense, share dilution, and cash obligations.
The employment agreement will be filed with the company’s Form 10-Q for the nine months ending September 30, 2022. The company also expects to enter into its standard indemnification agreement with Dr. Chou.
Investor Verification Items
- Review the employment agreement when filed in the Form 10-Q for complete definitions, vesting terms, and termination provisions.
- Verify the final option grant date, exercise price, and resulting potential dilution.
- Assess the effect of the CEO compensation and severance arrangements on future operating expenses and liquidity.
- Review subsequent filings for additional management changes or amendments to the compensation arrangements.